N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 2 ClinicalTrials.gov

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

Sponsor: Emory University • ClinicalTrials.gov ID: NCT05998135

Registry updated: 2026-10-01
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

This phase II trial test tests how well repurposing atovaquone works in treating patients with platinum-resistant ovarian cancer. Atovaquone is used for the treatment or prevention of certain infections. Atovaquone is in a class of medications called antiprotozoal agents. It works by stopping the growth of certain types of protozoa that can cause pneumonia. Giving atovaquone may be effective in treating platinum-resistant ovarian cancer and result in improved outcomes compared to standard chemotherapy regimens.

Interventions

  • Atovaquone (Drug)
    Given PO
  • Biopsy (Procedure)
    Undergo biopsy
  • Computed Tomography (Procedure)
    Undergo CT
  • Paracentesis (Procedure)
    Undergo paracentesis

Eligibility criteria

Inclusion Criteria: * Patients with platinum-resistant, high-grade serous ovarian cancer, defined as disease progression within six months of completion of their last platinum-based chemotherapy * Patients must maintain Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * There will be no limitations on number of prior lines of therapy * Trial is open to non-English speaking patients * Trial is open to patients referred from community practice Exclusion Criteria: * Patients who are \< 18 years old * Patients who are pregnant or breastfeeding (due to cancer of their reproductive organs, patients enrolled in the trial are unable to conceive) * Patients who are incarcerated * Patients who are unable to provide consent / lack decision-making capacity

Conditions

Ovarian High Grade Serous Adenocarcinoma Platinum-Resistant Ovarian Carcinoma

Locations

  • Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia, United States
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record